XINTELA TO SPIN OUT ONCOLOGY BUSINESS

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]

Xintela signs Letter of Intent with CO.DON

Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]

Xintela receives MUMS-status for the treatment of osteoarthritis in horses

Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]

Xintela prepares for oncology spinout

Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]

Year-end Report 2017

Strategic decisions, collaboration agreements and financing Xintela took major steps forward in 2017 and there is every reason to be optimistic about the new year. Our unique stem cell technology and the decision to establish our own GMP facility for stem cell production have made us a player to reckon with in regenerative medicine. We […]

Xintela licenses human antibody technology for cancer therapy

Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela’s markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela’s cancer products can be tested […]

Xintela to collaborate with Japanese CellSeed Inc.

Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint. “It is very exciting that we have established a collaboration in Japan which, due to a […]